Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables - Net (2016 - 2025)

Ultragenyx Pharmaceutical has reported Receivables - Net over the past 11 years, most recently at $1.0 million for Q4 2025.

  • Quarterly Receivables - Net fell 99.18% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 99.18% year-over-year, with the annual reading at $1.0 million for FY2025, 99.18% down from the prior year.
  • Receivables - Net was $1.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $1.7 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $124.5 million in Q2 2025 and troughed at $1.0 million in Q4 2025.
  • The 5-year median for Receivables - Net is $28.0 million (2021), against an average of $41.0 million.
  • Year-over-year, Receivables - Net surged 476.17% in 2024 and then tumbled 99.18% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $28.4 million in 2021, then dropped by 3.28% to $27.5 million in 2022, then surged by 42.55% to $39.2 million in 2023, then skyrocketed by 211.22% to $122.0 million in 2024, then tumbled by 99.18% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Receivables - Net are $1.0 million (Q4 2025), $1.7 million (Q3 2025), and $124.5 million (Q2 2025).